UnitedHealth Group (NYSE:UNH | UNH Price Prediction) delivered its most convincing quarter in over a year on April 21, 2026, posting a 9.38% EPS beat and raising full-year guidance, sending shares up 6.96% on the day to close at $346.01. After three consecutive quarters of margin deterioration and a catastrophic Q4 2025 GAAP EPS collapse to $0.01, investors got the turnaround signal they had been waiting for: a medical cost ratio that snapped back sharply and guidance that moved higher.
Q1 2026 Earnings Scorecard
| Category | Grade | Key Insight |
|---|---|---|
| Revenue Performance | B+ | $111.72B reported vs. $109.66B estimated, a 1.88% beat with 1.96% YoY growth; solid top-line expansion anchored by UnitedHealthcare Community & State revenue rising 4% YoY to $24.07B, driven by Medicaid rate updates. |
| Earnings Beat/Miss | A | Reported EPS of $7.23 vs. the $6.61 consensus estimate, a 9.38% beat; a sharp reversal from the 8.27% EPS miss in Q2 2025 and near-zero GAAP result in Q4 2025. |
| Forward Guidance | A- | Full-year 2026 adjusted EPS guidance raised to greater than $18.25, up from the prior $17.75 target set in Q4 2025; management committed to at least $2.0B in share buybacks through end of Q2 2026. |
| Profit Margins | B+ | Medical cost ratio improved 90 basis points to 83.9%, a dramatic recovery from the 89.9% MCR in Q3 2025; UnitedHealthcare operating margin expanded 40 basis points to 6.6%, though operating cost ratio widened to 13.8% from 12.4% due to AI and cybersecurity investment. |
| Cash Generation | A | Operating cash flow surged 63.34% YoY to $8.91B, equal to 1.4x net income; the company paid $2.01B in dividends in Q1 while holding $31.23B in cash and equivalents. |
| Management Tone | B+ | CEO Stephen Hemsley stated: “We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity.” Tone was measured and constructive, though DOJ legal actions and Medicare Advantage membership losses of 965,000 temper enthusiasm. |
Bottom Line
Q1 2026 is the clearest evidence that UnitedHealth’s managed care business is stabilizing. The MCR improvement to 83.9% matters most: after peaking at 89.9% in Q3 2025, cost discipline and repricing across all business lines are working. Medicaid rate updates flow through Community & State revenues, and specialty pharmacy growth lifts Optum Rx to $35.74B in revenue. Analysts hold a consensus target of $363.19, with 22 buy or strong buy ratings vs. just 2 sell ratings. The key watch for Q2 2026 is whether Optum Health, which saw revenues fall 3% YoY to $24.11B from fewer value-based care members, reverses that decline as membership stabilizes. If the MCR holds near current levels and Optum recovers, the raised full-year guidance of greater than $18.25 in adjusted EPS looks achievable.
Top Gaining Stocks
Top Losing Stocks